August 25, 2016
BTG International Canada Inc. announced it received Health Canada approval for DC Bead Lumi. The bead is the first such device available commercially for patients with hepatocellular carcinoma and colorectal cancer metastasized to the liver.
“DC Bead Lumi reinforces our leadership in embolization technology and our focus on bringing to market innovative products that better serve specialist physicians and their patients,” Brad Pearson, director of commercial operations of BTG International Canada Inc. said in a press release. “We are excited by the potential to offer a new standard of care.“